Prelude Capital Management, LLC Madrigal Pharmaceuticals, Inc. Transaction History

Prelude Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$193.33 - $291.99 $89,705 - $135,483	464 Added 22.79%	2,500 $700,000
Q1 2024 May 15, 2024	SELL	$171.37 - $283.23 $165,200 - $273,033	-964 Reduced 32.13%	2,036 $543,000
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $118,112 - $232,624	981 Added 48.59%	3,000 $694,000
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $99,015 - $153,078	678 Added 50.56%	2,019 $294,000
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $273,403 - $418,392	1,341 New	1,341 $309,000
Q2 2018 Aug 14, 2018	BUY	$101.55 - $313.9 $2,538 - $7,847	25 New	25 $7,000

296

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.94B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.